These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37513471)

  • 1.
    Miyamoto-Sato E; Imanishi S; Huang L; Itakura S; Iwasaki Y; Ishizaka M
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
    Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
    Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of GTPase KRAS
    Li Y; Yang L; Li X; Zhang X
    Expert Opin Ther Pat; 2024 Aug; 34(8):701-721. PubMed ID: 38884569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
    Zhou X; Ji Y; Zhou J
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
    Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
    Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
    Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
    J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS
    Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
    Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
    Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
    Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glimmers of hope for targeting oncogenic KRAS-G12D.
    Tang D; Kang R
    Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Heterozygosity for
    Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.
    Monticone M; Biollo E; Maffei M; Donadini A; Romeo F; Storlazzi CT; Giaretti W; Castagnola P
    Mol Cancer; 2008 Dec; 7():92. PubMed ID: 19087308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Targeted Degradation Strategy for Oncogenic KRAS
    Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor efficacy of a potent and selective non-covalent KRAS
    Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
    Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.